MJRX.CN stock jumps 57% to C$0.055 on CNQ 16 Feb 2026: momentum worth watching

MJRX.CN stock led Canadian small-caps today after a 57.14% intraday move to C$0.055 on the CNQ exchange on 16 Feb 2026. We flagged the surge during market hours as volume rose to 5,000 shares, nearly double the 3-month average of 2,648. The spike follows continued interest in the cannabis and psilocybin research niche where Global Health Clinics Ltd. operates. We review price drivers, valuation, technical signals, and what the Meyka AI forecast and grade say about the stock’s short-term outlook.

MJRX.CN stock: intraday price action and liquidity

Global Health Clinics Ltd. (MJRX.CN) opened at C$0.06, traded between C$0.055 and C$0.06, and closed higher than yesterday’s C$0.035. The one-day change of C$0.020 equals a 57.142857% gain, driven by thin but elevated volume of 5,000 shares.

Relative volume of 1.89 versus the 50-day average suggests retail-driven momentum. Low market cap (C$516,568) and 9,392,138 shares outstanding make MJRX.CN sensitive to small orders and news flow on CNQ in Canada.

Earnings, financials and valuation snapshot

MJRX.CN shows trailing EPS of -0.14 and a negative PE of -0.39, reflecting losses. Market metrics include price-to-sales 16.87, price-to-book -0.106, and enterprise value of C$2,562,302, indicating a stretched valuation versus tiny revenue per share of 0.0033.

Operating cash flow per share is -0.0622 and cash per share is 0.0061, while the current ratio is 0.0133. These figures show limited liquidity and negative working capital, raising execution risk despite recent revenue and cash flow improvements year-over-year.

Technicals and momentum behind the top-gainer move

Momentum indicators pushed MJRX.CN higher: RSI is 58.21, ROC is 83.33%, and CCI reads 116.88, signaling strong short-term momentum. Price sits above the 50-day average of C$0.035 and the 200-day average of C$0.02153, reflecting a near-term trend reversal.

Bollinger bands are 0.02/0.04/0.06, ATR is 0.01, and a tight trading range increases the risk of quick reversals. Traders should note year high at C$0.09 as the immediate resistance level.

Meyka AI rates and forecast for MJRX.CN

Meyka AI rates MJRX.CN with a score out of 100: 71.13 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and industry performance. These grades are informational and not financial advice.

Meyka AI’s forecast model projects a monthly price of C$0.05, a quarterly price of C$0.04, and a yearly projection of C$0.028365 compared with the current price of C$0.055. Those model-based projections imply short-term downside of about -9.09% (monthly) and -48.43% (yearly). Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context

Global Health Clinics Ltd. operates in Healthcare, specifically Drug Manufacturers – Specialty & Generic, with a focus on cannabis clinics and psilocybin product development. The healthcare sector has seen moderate gains YTD, but MJRX.CN faces regulatory and commercialization risks unique to cannabis and psychedelic research.

Additional risks include very low liquidity, negative book value per share (-0.5176), and mixed third-party ratings (company rating: C, recommendation: Sell dated 12 Feb 2026). Catalysts would include clinical data, licensing wins, or material partnerships that raise revenue visibility.

Short-term trading view and realistic price targets

For market analysis, a near-term price target at the year high of C$0.09 represents upside of 63.64% from C$0.055. A conservative short-term target near C$0.07 implies upside of 27.27% and aligns with recent intraday resistance.

Given the stock’s low float and volume, intraday traders may see rapid moves. Long-term investors should weigh the Meyka grade and forecast, sector risks, and the company’s weak liquidity before adding MJRX.CN stock to portfolios.

Final Thoughts

MJRX.CN stock delivered a sharp intraday gain of 57.14% to C$0.055 on CNQ during market hours on 16 Feb 2026, led by thin liquidity and momentum signals. Technical indicators show buying pressure, but core financials remain weak: negative EPS -0.14, current ratio 0.0133, and negative book value per share. Meyka AI rates the stock 71.13 (B+, BUY) while its forecast model projects monthly C$0.05 and yearly C$0.028365, implying potential short-term downside in the model outputs. For traders, watch resistance at C$0.07–0.09 and volume confirmation before sizing positions. For investors, the combination of regulatory uncertainty, low liquidity, and negative fundamentals argues for cautious position sizing and clear risk limits. Meyka AI’s real-time grade and forecasts offer a data-driven lens, but these projections are model-based and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.